Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the observational study is to ascertain the degree of blood pressure control in the early-morning hours after 8 weeks of treatment with Telmisartan/Telmisartan+Hydrochlorothiazide and during 44 weeks of follow-up, in patients with hypertension using home blood pressure measurements.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| telmisartan | Drug |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in mean early morning systolic blood pressure, mean early morning diastolic blood pressure, and degree of control. (6:00 to 11:59), BP < 135/85 mmHg. (HBPM: mean of morning measurements). | 217 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical control (office BP), response rates, reduction in office cuff systolic and diastolic BP. Office BP control criteria: BP < 140/90 mmHg. Pulse rate, pulse pressure, discontinuations and tolerability. | 217 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Primary Care Clinic
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Belgium | ||||
| Boehringer Ingelheim Investigational Site |
Not provided
Not provided
Not provided
Not provided
| Boehringer Ingelheim Investigational Site |
| Canada |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Colombia |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Czechia |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Ecuador |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Indonesia |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Jordan |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Lebanon |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Mexico |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Turkey (Türkiye) |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Venezuela |
| Boehringer Ingelheim Investigational Site | Boehringer Ingelheim Investigational Site | Yemen |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077333 | Telmisartan |
| ID | Term |
|---|---|
| D001713 | Biphenyl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001562 | Benzimidazoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided